In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum

scientific article

In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1046722588
P356DOI10.1186/1475-2875-13-189
P932PMC publication ID4045961
P698PubMed publication ID24886347
P5875ResearchGate publication ID262789114

P50authorBruno PradinesQ60044507
P2093author name stringEric Baret
Rémy Amalvict
Hélène Savini
Jérome Dormoi
P2860cites workPfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in CambodiaQ21034146
Artemisinin Resistance in Plasmodium falciparum MalariaQ22061852
Evidence of Artemisinin-Resistant Malaria in Western CambodiaQ22061854
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malariaQ27338288
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporterQ28375489
Synchronization of Plasmodium falciparum Erythrocytic Stages in CultureQ29547549
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy numberQ29615128
Pharmacogenetics of antimalarial drugs: effect on metabolism and transportQ34020238
In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter geneQ34478084
Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytesQ34620579
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemicQ34648820
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damageQ34669052
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine modelQ35753471
Role of P-glycoprotein in statin drug interactionsQ36634221
In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genesQ36757694
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine modelQ36798357
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine modelQ37152937
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate studyQ37205700
Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markersQ37263344
Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses.Q37335774
Preventing antimalarial drug resistance through combinationsQ39589995
Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areasQ39757934
Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates.Q39762005
[Antimalarial drug resistance]Q40474269
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoproteinQ40789773
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparumQ40936537
In vitro metabolism of piperaquine is primarily mediated by CYP3A4.Q41625322
Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 geneQ41935781
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malariaQ41938814
Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malariaQ41940260
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisininQ41944932
Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparumQ42623845
Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisininQ42929766
Statins alone are ineffective in cerebral malaria but potentiate artesunateQ43185216
Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatinQ43194042
Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophagesQ43264846
Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic studyQ80149477
P921main subjectPlasmodium falciparumQ311383
lumefantrineQ904464
P304page(s)189
P577publication date2014-05-25
P1433published inMalaria JournalQ15749954
P1476titleIn vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
P478volume13

Reverse relations

cites work (P2860)
Q100760581Determination of lumefantrine as an effective drug against Toxoplasma gondii infection - in vitro and in vivo study
Q58568707Malaria, tuberculosis and HIV: what's new? Contribution of the Institut Hospitalo-Universitaire Méditerranée Infection in updated data
Q56355687Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers
Q27974336Plasmodium falciparum Werner homologue is a nuclear protein and its biochemical activities reside in the N-terminal region
Q57167324Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity

Search more.